ArticleFrontiers in immunology2018
IgA Targeting Human Immunodeficiency Virus-1 Envelope gp41 Triggers Antibody-Dependent Cellular Cytotoxicity Cross-Clade and Cooperates with gp41-Specific IgG to Increase Cell Lysis.
Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 31 citations in OpenAlex.
- Difference in respiratory syncytial virus-specific Fc-mediated antibody effector functions between children and adults.Clinical and experimental immunology · 2023Review
- Antibody Fc-chimerism and effector functions: When IgG takes advantage of IgA.Frontiers in immunology · 2023Review
- Serum immunogloblins might be useful predictors of immune-related adverse events after immune checkpoint inhibitor usage in lung cancer.Thoracic cancer · 2022Article
- Antiviral Activities of HIV-1-Specific Human Broadly Neutralizing Antibodies Are Isotype-Dependent.Vaccines · 2022Article
- Epitope convergence of broadly HIV-1 neutralizing IgA and IgG antibody lineages in a viremic controller.The Journal of experimental medicine · 2022Article
- Article
- B cell class switching in intestinal immunity in health and disease.Scandinavian journal of immunology · 2022Review
- Persistent but dysfunctional mucosal SARS-CoV-2-specific IgA and low lung IL-1β associate with COVID-19 fatal outcome: A cross-sectional analysis.Frontiers in immunology · 2022Article
- IgA potentiates NETosis in response to viral infection.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- TLR-Agonist Mediated Enhancement of Antibody-Dependent Effector Functions as Strategy For an HIV-1 Cure.Frontiers in immunology · 2021Review
- The CH1α domain of mucosal gp41 IgA contributes to antibody specificity and antiviral functions in HIV-1 highly exposed Sero-Negative individuals.PLoS pathogens · 2020Article
- Comparative Evaluation of Prophylactic SIV Vaccination Modalities Administered to the Oral Cavity.AIDS research and human retroviruses · 2020Article
- A Zigzag but Upward Way to Develop an HIV-1 Vaccine.Vaccines · 2020Review
- Recent insights into Fc-mediated effector responses to HIV-1.Current opinion in HIV and AIDS · 2020Review
- VSV-Displayed HIV-1 Envelope Identifies Broadly Neutralizing Antibodies Class-Switched to IgG and IgA.Cell host & microbe · 2020Article
- Serum IgA Fc effector functions in infectious disease and cancer.Immunology and cell biology · 2020Review
- The Protective HIV-1 Envelope gp41 Antigen P1 Acts as a Mucosal Adjuvant Stimulating the Innate Immunity.Frontiers in immunology · 2020Article
- New GMP manufacturing processes to obtain thermostable HIV-1 gp41 virosomes under solid forms for various mucosal vaccination routes.NPJ vaccines · 2020Article
- Antibody-Dependent Cellular Phagocytosis of HIV-1-Infected Cells Is Efficiently Triggered by IgA Targeting HIV-1 Envelope Subunit gp41.Frontiers in immunology · 2020Article
- IgA and FcαRI: Versatile Players in Homeostasis, Infection, and Autoimmunity.ImmunoTargets and therapy · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The protective efficacy of human immunodeficiency virus-1 (HIV-1) antibodies (Abs) remains mostly correlated with their
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.